- Integration
- DICOM import, processing, and export to PACS or a workstation; validate transfer syntax, identifiers, series labels, geometry, and failure handling.
FDA source Exact FDA submission Checked 2026-09-03
- Deployment and data flow
- Release-specific software server or workstation installed in the clinical imaging environment.
FDA source Exact FDA submission Checked 2026-09-03
- Security and privacy
- Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-03
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
- Training and support
- Only qualified mri technologists and interpreting physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-03
- Monitoring and change control
- Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA summary identifies a limitation for lesions, masses, or abnormalities smaller than 1.5 mm. Confirm the exact sequence, image-size, server, and output constraints and review processed images against source images.
FDA source Exact FDA submission Checked 2026-09-03
Release and scope verification
Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K173605 before acceptance.
exact submission · checked 2026-09-03 Later product-family features are not evidence that this cleared release includes them.
Interoperability acceptance
DICOM import, processing, and export to PACS or a workstation; validate transfer syntax, identifiers, series labels, geometry, and failure handling.
exact submission · checked 2026-09-03 Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. The capability is derived from the exact FDA workflow and still requires local acceptance testing.
Clinical acceptance
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA summary identifies a limitation for lesions, masses, or abnormalities smaller than 1.5 mm. Confirm the exact sequence, image-size, server, and output constraints and review processed images against source images.
exact submission · checked 2026-09-03 Define stop-use, escalation, rollback, and revalidation triggers before production use.
Economic evaluation
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03 No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.
Lifecycle monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA summary identifies a limitation for lesions, masses, or abnormalities smaller than 1.5 mm. Confirm the exact sequence, image-size, server, and output constraints and review processed images against source images.
exact submission · checked 2026-09-03 Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. The capability is derived from the exact FDA workflow and still requires local acceptance testing.